The Immune-Mediated Inflammatory Disease Forum
The IMID Forum
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
Author
The Immune-Mediated Inflammatory Disease Forum
Category
Podcast website
Latest episode
Jul 9, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Discussing RA: Insights into Filgotinib and Tofacitinib in RA 19.12.2024 24:13
Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.
ACR 2024 Review Podcast 28.11.2024 50:04
ACR 2024 Review Podcast by The Immune-Mediated Inflammatory Disease Forum
Discussing PsA: DISCOVER-2 and BE OPTIMAL/BE COMPLETE post-hoc analyses 28.11.2024 30:53
Join Professors Peter Nash and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a post hoc analysis examining the rapid and sustained efficacy of bimekizumab in PsA patients across different subgroups, focusing on improvements in pain, fatigue, and physical function over 16 weeks. The conversation also covered a long-term analysis of gusel...
Discussing RA: Insights into Filgotinib and Tofacitinib in RA 14.11.2024 19:16
Join Professor Iain McInnes and Professor Johannes Bijlsma for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.
Webinar Highlights Podcast: CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases 13.11.2024 26:39
Webinar Highlights Podcast: Join Professor Iain McInnes and Professor Georg Schett as they discuss the recent webinar hosted on the IMID Forum: “CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases”. Listen to them discuss key highlights from the webinar including the development of CAR T-cell therapy, the application of CAR T to autoimmune diseases, and the potential risks and reservati...
ACR 2024: Preview Podcast 11.11.2024 19:51
ACR 2024: Preview Podcast by The Immune-Mediated Inflammatory Disease Forum
ACR 2024 Highlights: Day 1 11.11.2024 2:55
ACR 2024 Highlights: Day 1 by The Immune-Mediated Inflammatory Disease Forum
ACR 2024 Highlights: Day 2 11.11.2024 3:36
ACR 2024 Highlights: Day 2 by The Immune-Mediated Inflammatory Disease Forum
ACR 2024 Highlights: Day 3 11.11.2024 4:21
ACR 2024 Highlights: Day 3 by The Immune-Mediated Inflammatory Disease Forum
AxSpA Podcast: Efficacy and Safety of IV secukinumab 31.10.2024 23:30
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, and Atul Deodhar to discuss a recent study on the efficacy and safety of IV secukinumab in patient with active axSpA.
Discussing RA: Navigating JAKis, TNFis, and the quest for optimal RA therapy 31.10.2024 22:03
Join Professor Iain McInnes and Professor Leonard Calabrese for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the efficacy and safety of JAK inhibitors and TNF inhibitors for rheumatoid arthritis, while also uncovering the best treatment strategies for diffic...
Author Interview: Derin Karacabeyli, 2024 10.10.2024 33:27
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Derin Karacabeyli of Arthritis Research Canada, a rheumatologist and resident in the University of British Columbia Clinician Investigator Program, as they discuss his recent paper ‘Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated in...
Webinar Highlights Podcast 2: Evolving Therapeutic Strategies for Psoriatic Diseases 07.10.2024 32:56
Webinar Highlights Podcast: Join Professor Christopher Ritchlin, and Professor Philip Mease as they discuss the recent webinar hosted on the IMID Forum ‘Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2’. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the similarities and differences in pathology in skin and...
PsA Podcast: Bimekizumab: Efficacy, safety, and effectiveness in PsA 26.09.2024 21:04
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a matching-adjusted indirect comparison (MAIC) to assess the comparative efficacy of bimekizumab and risankizumab in patients with psoriatic arthritis over 52 weeks, and a post hoc analysis investigating the efficacy and safety of bimekizumab in...
Discussing RA: Long-term safety and efficacy of upadacitinib in SELECT trials 19.09.2024 19:24
Join Professor Iain McInnes and Professors Hideto Kameda and Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the long-term efficacy and safety of upadacitinib in the SELECT trials.
Discussing AxSpA: Incidence of uveitis following bimekizumab treatment 29.08.2024 24:11
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.
Author Interview: Professor Laura Andreoli, 2024 22.08.2024 44:09
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Laura Andreoli, a Professor of Rheumatology at the University of Brescia, as they discuss her recent paper ‘The outcomes of children born to mothers with autoimmune rheumatic diseases’, published in The Lancet. Rheumatology on 11th June 2024.
Discussing RA: Neutrophil-to-lymphocyte ratio and treatment response to filgotinib 15.08.2024 16:05
Join Professor Iain McInnes and Professors Hideto Kameda and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss a paper that investigated whether the baseline neutrophil-to-lymphocyte ratio had an effect on the treatment response to filgotinib.
Discussing AxSpA: Bimekizumab in AxSpA & Secukinumab Patient Clustering 12.08.2024 26:26
Join us for the latest axSpA podcast brought to you by the CSF! This month Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Leiden University Medical Centre and Zuyderland Medical Centre, is joined once again by experts with a wealth of clinical knowledge. Joining her is Hideto Kameda, Professor of Internal Medicine at Toho University as well as Atul Deodhar, Professor of Medici...
Discussing PsA: Secukinumab & The Effect of Sex on the Long-Term Persistence of Targeted Therapies 12.08.2024 30:33
Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, namely the effect of sex on the long-term persistence of targeted therapies, as well as the impact of secukinumab on synovitis and enthesitis.
Discussing AxSpA: Long-Term Outcomes of Secukinumab & JAKis in Clinical Practice 12.08.2024 25:05
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the long-term impact of secukinumab treatment on bone-related outcomes and BTMs in r-AxSpA patients over two years. Our faculty then move on to discuss another publication, which presents JAKi treat...
Discussing RA: January 2024 12.08.2024 9:43
Join Professor Iain McInnes for the first episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that aimed to advise on treatment of rheumatic diseases in a real-world setting. In our first paper, Emma Dures and her colleagues compiled the 2023 EULAR recommendations for the management...
Discussing PsA: Clinical Response to Guselkumab & Sequential Lines of b/tsDMARDs 12.08.2024 32:10
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the clinical response to guselkumab and the research surrounding sequential lines of b/tsDMARDs.
Discussing RA: February 2024 12.08.2024 10:17
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that show the long-term safety and efficacy of JAK inhibitors, both of which have a study period of 6.5 years. In our first paper, Roberto Caporali and colleagues show long-term safety and...
Discussing AxSpA: Risk of Uveitis with Different bDMARDs & PROs following Secukinumab Treatment 12.08.2024 32:38
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the risk of acute anterior uveitis across different bDMARDs in patients with AS. Our faculty then move on to discuss another publication, which compares patient-reported outcomes (PROs...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.